Evidence for brain glucose dysregulation in Alzheimer's disease

Alzheimer's and Dementia

Volumn 14, Issue 3, 2018, Pages 318-329

  An, Yang ^a   Varma, Vijay R ^a   Varma, Sudhir ^b   Casanova, Ramon ^c   Dammer, Eric ^d   Pletnikova, Olga ^e   Chia, Chee W ^a   Egan, Josephine M ^a   Ferrucci, Luigi ^a   Troncoso, Juan ^e   Levey, Allan I ^d   Lah, James ^d   Seyfried, Nicholas T ^d   Legido Quigley, Cristina ^f   O'Brien, Richard ^g   Thambisetty, Madhav ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Hithru   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Glucose; GLUT1; GLUT3; Glycolysis; Insulin resistance; Mass spectrometry; Neuritic plaque; Neurofibrillary tangles

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ALANINE; BRAIN PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLYCINE; HEXOKINASE; NESPRIN 1; PYRUVATE KINASE; SERINE; UNCLASSIFIED DRUG; SLC2A1 PROTEIN, HUMAN; SLC2A3 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; AUTOPSY; BRAIN TISSUE; CEREBELLUM; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN TISSUE; INFERIOR TEMPORAL GYRUS; MALE; MIDDLE FRONTAL GYRUS; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; BRAIN; LONGITUDINAL STUDY; MARYLAND; METABOLISM; METABOLOMICS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BALTIMORE; BRAIN; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLOMICS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 85033232213     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.09.011     Document Type: Article

References (48)

1. Leibson, C.L., Rocca, W.A., Hanson, V.A., Cha, R., Kokmen, E., O'Brien, P.C., et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145 (1997), 301–308.
2. Luchsinger, J.A., Tang, M.X., Stern, Y., Shea, S., Mayeux, R., Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154 (2001), 635–641.
3. Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., Breteler, M.M., Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 (1999), 1937–1942.
4. Chen, Z., Zhong, C., Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108 (2013), 21–43.
5. Hoyer, S., Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35 (2000), 1363–1372.
6. Ahmed, S., Mahmood, Z., Zahid, S., Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci 36 (2015), 1763–1769.
7. Chami, B., Steel, A.J., De La Monte, S.M., Sutherland, G.T., The rise and fall of insulin signaling in Alzheimer's disease. Metab Brain Dis 31 (2016), 497–515.
8. Freude, S., Schilbach, K., Schubert, M., The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 6 (2009), 213–223.
9. Hokama, M., Oka, S., Leon, J., Ninomiya, T., Honda, H., Sasaki, K., et al. Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex 24 (2014), 2476–2488.
10. Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122 (2012), 1316–1338.
11. de la Monte, S.M., Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol 24 (2014), 1954–1960.
12. de la Monte, S.M., Wands, J.R., Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2 (2008), 1101–1113.
13. Claxton, A., Baker, L.D., Hanson, A., Trittschuh, E.H., Cholerton, B., Morgan, A., et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 44 (2015), 897–906.
14. Claxton, A., Baker, L.D., Wilkinson, C.W., Trittschuh, E.H., Chapman, D., Watson, G.S., et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis 35 (2013), 789–797.
15. Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 (2008), 440–448.
16. Benarroch, E.E., Brain glucose transporters: implications for neurologic disease. Neurology 82 (2014), 1374–1379.
17. Simpson, I.A., Carruthers, A., Vannucci, S.J., Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 27 (2007), 1766–1791.
18. Joost, H.G., Thorens, B., The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 18 (2001), 247–256.
19. Herholz, K., Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Rev Neurother 10 (2010), 1667–1673.
20. Hunt, A., Schonknecht, P., Henze, M., Seidl, U., Haberkorn, U., Schroder, J., Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res 155 (2007), 147–154.
21. Jagust, W.J., Haan, M.N., Eberling, J.L., Wolfe, N., Reed, B.R., Functional imaging predicts cognitive decline in Alzheimer's disease. J Neuroimaging 6 (1996), 156–160.
22. Mosconi, L., Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32 (2005), 486–510.
23. Ferrucci, L., The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci 63 (2008), 1416–1419.
24. Shock, N.W., Gruelich, R., Andres, R., Arenberg, D., Costa, P.T., Lakatta, E., et al. Normal human aging. The Baltimore Longitudinal Study of Aging. 1984, US Government Printing Office, Washington, DC.
25. O'Brien, R.J., Resnick, S.M., Zonderman, A.B., Ferrucci, L., Crain, B.J., Pletnikova, O., et al. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis 18 (2009), 665–675.
26. Gamaldo, A., Moghekar, A., Kilada, S., Resnick, S.M., Zonderman, A.B., O'Brien, R., Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 67 (2006), 1363–1369.
27. Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R. Washington, D.C.: American Psychiatric Association; 1994.
28. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
29. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991), 479–486.
30. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta neuropathol 82 (1991), 239–259.
31. Troncoso, J.C., Zonderman, A.B., Resnick, S.M., Crain, B., Pletnikova, O., O'Brien, R.J., Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 64 (2008), 168–176.
32. Iacono, D., Resnick, S.M., O'Brien, R., Zonderman, A.B., An, Y., Pletnikova, O., et al. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent beta-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol 73 (2014), 295–304.
33. Metter, E.J., Windham, B.G., Maggio, M., Simonsick, E.M., Ling, S.M., Egan, J.M., et al. Glucose and insulin measurements from the oral glucose tolerance test and mortality prediction. Diabetes care 31 (2008), 1026–1030.
34. Larner, A.J., The cerebellum in Alzheimer's disease. Dement Geriatr Cogn Disord 8 (1997), 203–209.
35. Berg, J.M., Tymoczko, J.L., Stryer, L., Stryer, L., Biochemistry. 5th ed., 2002, W.H. Freeman, New York.
36. Vannucci, S.J., Maher, F., Simpson, I.A., Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21 (1997), 2–21.
37. Seyfried, N.T., Dammer, E.B., Swarup, V., Nandakumar, D., Duong, D.M., Yin, L., et al. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. Cell Syst 4 (2017), 60–72.e4.
38. Harrell, F.E., Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2015, Springer, Cham.
39. Dammer, E.B., Duong, D.M., Diner, I., Gearing, M., Feng, Y., Lah, J.J., et al. Neuron enriched nuclear proteome isolated from human brain. J Proteome Res 12 (2013), 3193–3206.
40. Reiman, E.M., Chen, K., Alexander, G.E., Caselli, R.J., Bandy, D., Osborne, D., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101 (2004), 284–289.
41. Duelli, R., Kuschinsky, W., Brain glucose transporters: relationship to local energy demand. News Physiol Sci 16 (2001), 71–76.
42. Simpson, I.A., Chundu, K.R., Davies-Hill, T., Honer, W.G., Davies, P., Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 35 (1994), 546–551.
43. Kalaria, R.N., Harik, S.I., Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 53 (1989), 1083–1088.
44. Dick, A.P., Harik, S.I., Klip, A., Walker, D.M., Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. Proc Natl Acad Sci U S A 81 (1984), 7233–7237.
45. Wahjudi, P.N., Patterson, M.E., Lim, S., Yee, J.K., Mao, C.S., Lee, W.N., Measurement of glucose and fructose in clinical samples using gas chromatography/mass spectrometry. Clin Biochem 43 (2010), 198–207.
46. Lentner, C., Geigy scientific tables, Vol. 1, 1981, Ciba-Geigy, Basle.
47. Wu, A.H.B., Tietz clinical guide to laboratory tests. 2006, Saunders Elsevier, St. Louis.
48. Thambisetty, M., Jeffrey Metter, E., Yang, A., Dolan, H., Marano, C., Zonderman, A.B., et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 70 (2013), 1167–1172.